MedRx Co., Ltd (TYO:4586)

Market Cap	7.42B +95.3%
Revenue (ttm)	128.00M -50.2%
Net Income	-937.00M
EPS	-17.44
Shares Out	59.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,839,700
Average Volume	1,243,080
Open	116.00
Previous Close	125.00
Day's Range	108.00 - 125.00
52-Week Range	55.00 - 225.00
Beta	0.80
RSI	64.22
Earnings Date	Feb 13, 2026

About MedRx

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which has completed phase Ib clinical trials for the treatment of spastic paralysis; MRX-9FLT that...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 22
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4586

Financial Performance

In 2025, MedRx's revenue was 128.00 million, a decrease of -50.19% compared to the previous year's 257.00 million. Losses were -937.00 million, 16.3% more than in 2024.